公开(公告)号：US09321757B2

公开(公告)日：2016-04-26

申请号：US14533326

申请日：2014-11-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D409/14 ,  C07D405/14 ,  C07D401/04 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20150266881A1

公开(公告)日：2015-09-24

申请号：US14435085

申请日：2013-10-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07D231/38 ,  C07C237/38 ,  C07C237/30 ,  C07D241/12 ,  C07D213/36 ,  C07D471/04 ,  C07D207/46 ,  C07D241/18 ,  C07D319/18 ,  C07D265/36 ,  C07D333/20 ,  C07D285/135 ,  C07D277/38 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D223/12 ,  C07D513/04 ,  C07C237/40

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物，可用作精神分裂症，阿尔茨海默病，帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物：其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1，R 2和R 3各自独立地为氢原子，任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合，与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合，与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。